Iteos – and GSK – keep the faith

The air is fast escaping the Tigit bubble, though some hope remains that Roche’s Skyscraper-01 trial could yet show a survival benefit, and Gilead has repeatedly played up its Arc-7 study. A much smaller Tigit player, Belgium’s Iteos, is far from giving up either.